[
  {
    "title": "泰格医药(300347.SZ)：董事ZHUAN YIN减持期过半未减持",
    "href": "http://stock.jrj.com.cn/2022/12/16164837218411.shtml",
    "datetime": "2022-12-16 16:48:56",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)股东曹晓春自公司上市以来累计减持比例为2.4548%",
    "href": "http://stock.jrj.com.cn/2022/12/07190937195938.shtml",
    "datetime": "2022-12-07 19:09:08",
    "code": "300347"
  },
  {
    "title": "泰格医药(300347.SZ)：曹晓春大宗交易减持550万股A股",
    "href": "http://stock.jrj.com.cn/2022/12/07180637195672.shtml",
    "datetime": "2022-12-07 18:06:08",
    "code": "300347"
  },
  {
    "title": "泰格医药(300347.SZ)：11月份未进行股份回购",
    "href": "http://stock.jrj.com.cn/2022/12/02173637184940.shtml",
    "datetime": "2022-12-02 17:36:58",
    "code": "300347"
  },
  {
    "title": "泰格医药(300347.SZ)：向817名激励对象首次授予607.9784万股限制性A股",
    "href": "http://stock.jrj.com.cn/2022/11/25174937167408.shtml",
    "datetime": "2022-11-25 17:49:41",
    "code": "300347"
  },
  {
    "title": "成交总金额约3.69亿元 泰格医药已回购约391万股公司股份",
    "href": "http://stock.jrj.com.cn/2022/11/03184637110581.shtml",
    "datetime": "2022-11-03 18:46:58",
    "code": "300347"
  },
  {
    "title": "港股异动 | 泰格医药AH齐涨 第三季度扣非净利润同比增长29.02%",
    "href": "http://stock.jrj.com.cn/2022/10/26095637084609.shtml",
    "datetime": "2022-10-26 09:56:49",
    "code": "300347"
  },
  {
    "title": "泰格医药2022年前三季度净利16.05亿同比下滑9.9% 支付第三方供应商相关费用增加",
    "href": "http://stock.jrj.com.cn/2022/10/25201137082984.shtml",
    "datetime": "2022-10-25 20:11:39",
    "code": "300347"
  },
  {
    "title": "泰格医药(300347.SZ)第三季度净利4.13亿元 同比下降21.56%",
    "href": "http://stock.jrj.com.cn/2022/10/25194537082902.shtml",
    "datetime": "2022-10-25 19:45:41",
    "code": "300347"
  },
  {
    "title": "泰格医药(300347.SZ)：聘任杨成成为财务负责人",
    "href": "http://stock.jrj.com.cn/2022/10/21200037074499.shtml",
    "datetime": "2022-10-21 20:00:11",
    "code": "300347"
  },
  {
    "title": "泰格医药(300347.SZ)9月份未回购A股股份",
    "href": "http://stock.jrj.com.cn/2022/10/11170537047365.shtml",
    "datetime": "2022-10-11 17:05:50",
    "code": "300347"
  },
  {
    "title": "泰格医药回应股价大跌：可能是补跌",
    "href": "http://stock.jrj.com.cn/2022/10/10134737043515.shtml",
    "datetime": "2022-10-10 13:47:24",
    "code": "300347"
  },
  {
    "title": "券业场|浙商证券原保代王建刚加盟民生证券，曾参与泰格医药、华峰化学等IPO项目",
    "href": "http://stock.jrj.com.cn/2022/09/13185736992048.shtml",
    "datetime": "2022-09-13 18:57:09",
    "code": "300347"
  },
  {
    "title": "泰格医药：网传消息主要针对临床前CRO业务 公司未涉及相关业务",
    "href": "http://stock.jrj.com.cn/2022/09/13115336990685.shtml",
    "datetime": "2022-09-13 11:53:07",
    "code": "300347"
  },
  {
    "title": "泰格医药(300347.SZ)：截至8月底已累计回购0.448%股份",
    "href": "http://stock.jrj.com.cn/2022/09/01201336964152.shtml",
    "datetime": "2022-09-01 20:13:35",
    "code": "300347"
  },
  {
    "title": "泰格医药(300347.SZ)：董事及高管ZHUAN YIN拟减持不超129.6万股",
    "href": "http://stock.jrj.com.cn/2022/08/26152336940672.shtml",
    "datetime": "2022-08-26 15:23:00",
    "code": "300347"
  },
  {
    "title": "泰格医药(300347.SZ)半年度净利润11.92亿元 同比下降5.02%",
    "href": "http://stock.jrj.com.cn/2022/08/25190636936807.shtml",
    "datetime": "2022-08-25 19:06:27",
    "code": "300347"
  },
  {
    "title": "泰格医药(300347.SZ)：已累计耗资约3.69亿元回购390.98万股",
    "href": "http://stock.jrj.com.cn/2022/08/02150936862695.shtml",
    "datetime": "2022-08-02 15:09:55",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)：何燕群担任公司秘书及授权代表",
    "href": "http://stock.jrj.com.cn/2022/06/27164936761416.shtml",
    "datetime": "2022-06-27 16:49:58",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)遭摩根大通减持60.83万股",
    "href": "http://stock.jrj.com.cn/2022/06/16071836733007.shtml",
    "datetime": "2022-06-16 07:18:37",
    "code": "300347"
  },
  {
    "title": "泰格医药(300347.SZ)：209.9011万股限制性股票将解除限售上市流通",
    "href": "http://stock.jrj.com.cn/2022/06/15193836732174.shtml",
    "datetime": "2022-06-15 19:38:52",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)遭Aggregate of abrdn plc减持107.89万股",
    "href": "http://stock.jrj.com.cn/2022/06/14072536726134.shtml",
    "datetime": "2022-06-14 07:25:11",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)遭Aggregate of abrdn plc减持130.84万股",
    "href": "http://stock.jrj.com.cn/2022/06/13072436722470.shtml",
    "datetime": "2022-06-13 07:24:02",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)遭Aggregate of abrdn plc减持116.24万股",
    "href": "http://stock.jrj.com.cn/2022/06/10074036717891.shtml",
    "datetime": "2022-06-10 07:40:44",
    "code": "300347"
  },
  {
    "title": "泰格医药(300347.SZ)：截至5月底累计耗资3.69亿元回购390.98万股",
    "href": "http://stock.jrj.com.cn/2022/06/01165736697204.shtml",
    "datetime": "2022-06-01 16:57:25",
    "code": "300347"
  },
  {
    "title": "方达控股(01521.HK)获泰格医药增持158.4万股",
    "href": "http://stock.jrj.com.cn/2022/06/01062536695149.shtml",
    "datetime": "2022-06-01 06:25:42",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)5月26日耗资2000.5万元回购25.25万股A股",
    "href": "http://stock.jrj.com.cn/2022/05/26171336681504.shtml",
    "datetime": "2022-05-26 17:13:41",
    "code": "300347"
  },
  {
    "title": "泰格医药(300347.SZ)：2021年度权益分派10派5元 股权登记日为5月30日",
    "href": "http://stock.jrj.com.cn/2022/05/24211836675555.shtml",
    "datetime": "2022-05-24 21:18:26",
    "code": "300347"
  },
  {
    "title": "方达控股：获泰格医药增持154万股",
    "href": "http://stock.jrj.com.cn/2022/05/12091336640403.shtml",
    "datetime": "2022-05-12 09:13:48",
    "code": "300347"
  },
  {
    "title": "方达控股(01521.HK)获泰格医药增持154万股",
    "href": "http://stock.jrj.com.cn/2022/05/12062736639833.shtml",
    "datetime": "2022-05-12 06:27:54",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)遭摩根大通减持38.73万股",
    "href": "http://stock.jrj.com.cn/2022/05/11071536628975.shtml",
    "datetime": "2022-05-11 07:15:50",
    "code": "300347"
  },
  {
    "title": "泰格医药(300347.SZ)：35.8115万股限制性股票将解除限售上市流通",
    "href": "http://stock.jrj.com.cn/2022/05/10193436623505.shtml",
    "datetime": "2022-05-10 19:34:48",
    "code": "300347"
  },
  {
    "title": "泰格医药(300347.SZ)：截至4月底累计耗资3亿元回购307.44万股",
    "href": "http://stock.jrj.com.cn/2022/05/05182836571045.shtml",
    "datetime": "2022-05-05 18:28:09",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)获摩根大通增持13.58万股",
    "href": "http://stock.jrj.com.cn/2022/05/04073836552352.shtml",
    "datetime": "2022-05-04 07:38:39",
    "code": "300347"
  },
  {
    "title": "泰格医药2022年第一季度净利5.18亿万同比增加13.82% 临床试验相关服务收入增加",
    "href": "http://stock.jrj.com.cn/2022/05/02171136533002.shtml",
    "datetime": "2022-05-02 17:11:51",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)4月29日耗资1006.9万元回购11.41万股A股",
    "href": "http://stock.jrj.com.cn/2022/04/29170636505127.shtml",
    "datetime": "2022-04-29 17:06:00",
    "code": "300347"
  },
  {
    "title": "麦格理：升泰格医药(3347.HK)评级至“跑赢大市”，目标价下调至88.6港元",
    "href": "http://stock.jrj.com.cn/2022/04/29135236503584.shtml",
    "datetime": "2022-04-29 13:52:36",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)遭摩根大通减持8.38万股",
    "href": "http://stock.jrj.com.cn/2022/04/29083836500332.shtml",
    "datetime": "2022-04-29 08:38:01",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)4月28日耗资3992.4万元回购46.79万股A股",
    "href": "http://stock.jrj.com.cn/2022/04/28172736493731.shtml",
    "datetime": "2022-04-28 17:27:36",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)获摩根大通增持8.3万股",
    "href": "http://stock.jrj.com.cn/2022/04/28070236489505.shtml",
    "datetime": "2022-04-28 07:02:30",
    "code": "300347"
  },
  {
    "title": "泰格医药第一季度营收约18.18亿元，同比增加101.55%",
    "href": "http://stock.jrj.com.cn/2022/04/26184536477379.shtml",
    "datetime": "2022-04-26 18:45:11",
    "code": "300347"
  },
  {
    "title": "泰格医药(300347.SZ)一季度净利润5.18亿元 同比增长13.82%",
    "href": "http://stock.jrj.com.cn/2022/04/26164936476195.shtml",
    "datetime": "2022-04-26 16:49:10",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)遭摩根大通减持11.22万股",
    "href": "http://stock.jrj.com.cn/2022/04/26073936471708.shtml",
    "datetime": "2022-04-26 07:39:04",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)获摩根大通增持22.85万股",
    "href": "http://stock.jrj.com.cn/2022/04/20072236405827.shtml",
    "datetime": "2022-04-20 07:22:46",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)遭摩根大通减持18.95万股",
    "href": "http://stock.jrj.com.cn/2022/04/11072236298638.shtml",
    "datetime": "2022-04-11 07:22:01",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)获摩根大通增持37.21万股",
    "href": "http://stock.jrj.com.cn/2022/04/08070136270638.shtml",
    "datetime": "2022-04-08 07:01:00",
    "code": "300347"
  },
  {
    "title": "泰格医药(300347.SZ)：截至3月底已累计回购249.24万股",
    "href": "http://stock.jrj.com.cn/2022/04/01172436247756.shtml",
    "datetime": "2022-04-01 17:24:47",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)获摩根大通增持36.19万股",
    "href": "http://stock.jrj.com.cn/2022/03/30094936183138.shtml",
    "datetime": "2022-03-30 09:49:56",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)年度经调整净利增长60.6%至15.85亿元",
    "href": "http://stock.jrj.com.cn/2022/03/28175835901841.shtml",
    "datetime": "2022-03-28 17:58:07",
    "code": "300347"
  },
  {
    "title": "泰格医药(300347.SZ)2021年度净利升64.26%至28.74亿元 拟10派5元",
    "href": "http://stock.jrj.com.cn/2022/03/28172935897396.shtml",
    "datetime": "2022-03-28 17:29:08",
    "code": "300347"
  },
  {
    "title": "泰格医药股东曹晓春质押35万股 用于补充质押",
    "href": "http://stock.jrj.com.cn/2022/03/14201334825659.shtml",
    "datetime": "2022-03-14 20:13:23",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)： 董事于禁售期内进行证券交易",
    "href": "http://stock.jrj.com.cn/2022/03/14183434825107.shtml",
    "datetime": "2022-03-14 18:34:34",
    "code": "300347"
  },
  {
    "title": "泰格医药今年1至2月新签订单同比增长超65%，盘中涨超7%",
    "href": "http://stock.jrj.com.cn/2022/03/11115534813088.shtml",
    "datetime": "2022-03-11 11:55:24",
    "code": "300347"
  },
  {
    "title": "泰格医药2021年净利28.74亿同比增长64.26% 股权转让收益增长",
    "href": "http://stock.jrj.com.cn/2022/03/10225434811420.shtml",
    "datetime": "2022-03-10 22:54:19",
    "code": "300347"
  },
  {
    "title": "泰格医药(300347.SZ)：预计1-2月营收同比增长超100%",
    "href": "http://stock.jrj.com.cn/2022/03/10194134810590.shtml",
    "datetime": "2022-03-10 19:41:19",
    "code": "300347"
  },
  {
    "title": "泰格医药(300347.SZ)业绩快报：2021年度净利升64.26%至28.74亿元",
    "href": "http://stock.jrj.com.cn/2022/03/10190734810447.shtml",
    "datetime": "2022-03-10 19:07:01",
    "code": "300347"
  },
  {
    "title": "靠增持和回购拉股价？泰格医药近半年跌超50%",
    "href": "http://stock.jrj.com.cn/2022/03/02171434512672.shtml",
    "datetime": "2022-03-02 17:14:13",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)获Ninety One UK增持32.08万股",
    "href": "http://stock.jrj.com.cn/2022/03/02064634510387.shtml",
    "datetime": "2022-03-02 06:46:30",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)：累计回购249.24万股A股",
    "href": "http://stock.jrj.com.cn/2022/03/01175034508842.shtml",
    "datetime": "2022-03-01 17:50:45",
    "code": "300347"
  },
  {
    "title": "泰格医药(300347.SZ)：本轮回购截至2月底累计耗资2.5亿元回购249.24万股",
    "href": "http://stock.jrj.com.cn/2022/03/01172634508636.shtml",
    "datetime": "2022-03-01 17:26:31",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)获Aggregate of abrdn plc增持22.51万股",
    "href": "http://stock.jrj.com.cn/2022/02/22065234431512.shtml",
    "datetime": "2022-02-22 06:52:38",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)2月21日耗资7913.33万元回购79.38万股A股",
    "href": "http://stock.jrj.com.cn/2022/02/21163634422692.shtml",
    "datetime": "2022-02-21 16:36:53",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)2月18日耗资4324.86万元回购42.55万股A股",
    "href": "http://stock.jrj.com.cn/2022/02/18163134392248.shtml",
    "datetime": "2022-02-18 16:31:50",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)2月17日耗资4953.42万元回购48.67万股A股",
    "href": "http://stock.jrj.com.cn/2022/02/17163534382090.shtml",
    "datetime": "2022-02-17 16:35:23",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)2月16日耗资2140.6万元回购21.39万股A股",
    "href": "http://stock.jrj.com.cn/2022/02/16165734370046.shtml",
    "datetime": "2022-02-16 16:57:29",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)遭摩根大通减持90.52万股",
    "href": "http://stock.jrj.com.cn/2022/02/16070234362043.shtml",
    "datetime": "2022-02-16 07:02:16",
    "code": "300347"
  },
  {
    "title": "泰格医药：首次回购1.66万股 成交总金额约163.48万元",
    "href": "http://stock.jrj.com.cn/2022/02/15172734354475.shtml",
    "datetime": "2022-02-15 17:27:12",
    "code": "300347"
  },
  {
    "title": "泰格医药(300347.SZ)：2月15日首次回购1.66万股",
    "href": "http://stock.jrj.com.cn/2022/02/15171134354190.shtml",
    "datetime": "2022-02-15 17:11:53",
    "code": "300347"
  },
  {
    "title": "港股异动 | 泰格医药AH股齐升 半年内两次回购股份用于股权激励",
    "href": "http://stock.jrj.com.cn/2022/02/15120134353052.shtml",
    "datetime": "2022-02-15 12:01:18",
    "code": "300347"
  },
  {
    "title": "泰格医药将花不超5亿元回购公司股份 用于股权激励",
    "href": "http://stock.jrj.com.cn/2022/02/14183234345617.shtml",
    "datetime": "2022-02-14 18:32:04",
    "code": "300347"
  },
  {
    "title": "港股异动 | 泰格医药(3347.HK)涨4.5%，拟回购2.5亿-5亿元A股",
    "href": "http://stock.jrj.com.cn/2022/02/14094634340149.shtml",
    "datetime": "2022-02-14 09:46:12",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)获Ninety One UK增持24.29万股",
    "href": "http://stock.jrj.com.cn/2022/02/14062834338201.shtml",
    "datetime": "2022-02-14 06:28:35",
    "code": "300347"
  },
  {
    "title": "泰格医药(300347.SZ)：拟以2.5亿-5亿元回购部分公司A股股份",
    "href": "http://stock.jrj.com.cn/2022/02/13174434334631.shtml",
    "datetime": "2022-02-13 17:44:47",
    "code": "300347"
  },
  {
    "title": "泰格医药(300347.SZ)：2020年A股员工持股计划锁定期将于2月1日届满",
    "href": "http://stock.jrj.com.cn/2022/01/26161034223304.shtml",
    "datetime": "2022-01-26 16:10:42",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)获Aggregate of abrdn plc增持26.54万股",
    "href": "http://stock.jrj.com.cn/2022/01/19072634172404.shtml",
    "datetime": "2022-01-19 07:26:35",
    "code": "300347"
  },
  {
    "title": "A股异动 | 泰格医药(300347.SZ)涨逾5% 预计年度净利润增长50%至73%",
    "href": "http://stock.jrj.com.cn/2022/01/13110134153170.shtml",
    "datetime": "2022-01-13 11:01:30",
    "code": "300347"
  },
  {
    "title": "泰格医药2021年预计净利26.25亿-30.27亿同比增长50%-73% 主营业务持续增长",
    "href": "http://stock.jrj.com.cn/2022/01/12215234151726.shtml",
    "datetime": "2022-01-12 21:52:40",
    "code": "300347"
  },
  {
    "title": "泰格医药(300347.SZ)：2021年预盈26.25亿元-30.27亿元，同比增长50%-73%",
    "href": "http://stock.jrj.com.cn/2022/01/12175934150626.shtml",
    "datetime": "2022-01-12 17:59:19",
    "code": "300347"
  },
  {
    "title": "泰格医药控股股东曹晓春质押160万股 用于个人融资",
    "href": "http://stock.jrj.com.cn/2021/12/31193234094259.shtml",
    "datetime": "2021-12-31 19:32:49",
    "code": "300347"
  },
  {
    "title": "泰格医药(300347.SZ)：持股5%以上股东曹晓春质押160万股",
    "href": "http://stock.jrj.com.cn/2021/12/31161734093231.shtml",
    "datetime": "2021-12-31 16:17:34",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)12月15日耗资80.36万元回购2.86万股A股",
    "href": "http://stock.jrj.com.cn/2021/12/15174834020164.shtml",
    "datetime": "2021-12-15 17:48:08",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)：ZHUAN YIN减持计划期限届满 未减持公司股份",
    "href": "http://stock.jrj.com.cn/2021/12/13163634008813.shtml",
    "datetime": "2021-12-13 16:36:55",
    "code": "300347"
  },
  {
    "title": "泰格医药(300347.SZ)：董事ZHUAN YIN减持到期未减持",
    "href": "http://stock.jrj.com.cn/2021/12/13163134008789.shtml",
    "datetime": "2021-12-13 16:31:56",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)遭摩根大通减持8.48万股",
    "href": "http://stock.jrj.com.cn/2021/12/09081633988363.shtml",
    "datetime": "2021-12-09 08:16:39",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)获摩根大通增持18.37万股",
    "href": "http://stock.jrj.com.cn/2021/12/07081133977832.shtml",
    "datetime": "2021-12-07 08:11:06",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)遭摩根大通减持8.92万股",
    "href": "http://stock.jrj.com.cn/2021/12/02082733953769.shtml",
    "datetime": "2021-12-02 08:27:14",
    "code": "300347"
  },
  {
    "title": "泰格医药(300347.SZ)：持股5%以上的曹晓春解押260万股",
    "href": "http://stock.jrj.com.cn/2021/11/29220933940226.shtml",
    "datetime": "2021-11-29 22:09:30",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)持股5%以上股东部分股份回购并解除质押",
    "href": "http://stock.jrj.com.cn/2021/11/29163933938247.shtml",
    "datetime": "2021-11-29 16:39:39",
    "code": "300347"
  },
  {
    "title": "泰格医药(300347.SZ)：曹晓春质押520万股及解押250万股",
    "href": "http://stock.jrj.com.cn/2021/11/22215733905757.shtml",
    "datetime": "2021-11-22 21:57:44",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)遭NINETY ONE UK减持110.53万股",
    "href": "http://stock.jrj.com.cn/2021/11/19070833877154.shtml",
    "datetime": "2021-11-19 07:08:29",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)遭摩根大通减持18.77万股",
    "href": "http://stock.jrj.com.cn/2021/11/15071833852413.shtml",
    "datetime": "2021-11-15 07:18:29",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)获Aggregate of abrdn plc增持40.13万股",
    "href": "http://stock.jrj.com.cn/2021/11/04074433811121.shtml",
    "datetime": "2021-11-04 07:44:39",
    "code": "300347"
  },
  {
    "title": "泰格医药(300347.SZ)：回购方案已实施完成",
    "href": "http://stock.jrj.com.cn/2021/11/01211133799914.shtml",
    "datetime": "2021-11-01 21:11:19",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)获贝莱德增持11.84万股",
    "href": "http://stock.jrj.com.cn/2021/11/01073633795070.shtml",
    "datetime": "2021-11-01 07:36:35",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)10月27日耗资4982.7万元回购31.33万股A股",
    "href": "http://stock.jrj.com.cn/2021/10/27163233761789.shtml",
    "datetime": "2021-10-27 16:32:17",
    "code": "300347"
  },
  {
    "title": "三季报陆续披露，高瓴已退出凯莱英、泰格医药等3家前十大流通股东名单",
    "href": "http://stock.jrj.com.cn/2021/10/27112033760305.shtml",
    "datetime": "2021-10-27 11:20:03",
    "code": "300347"
  },
  {
    "title": "泰格医药AH股齐拉升 业绩超预期",
    "href": "http://stock.jrj.com.cn/2021/10/25095133745563.shtml",
    "datetime": "2021-10-25 09:51:51",
    "code": "300347"
  },
  {
    "title": "泰格医药(300347.SZ)第三季度净利润5.26亿元 同比增长64.80%",
    "href": "http://stock.jrj.com.cn/2021/10/22164233733537.shtml",
    "datetime": "2021-10-22 16:42:58",
    "code": "300347"
  },
  {
    "title": "泰格医药(300347.SZ)截至9月底已累计回购269.92万股",
    "href": "http://stock.jrj.com.cn/2021/10/10102333663197.shtml",
    "datetime": "2021-10-10 10:23:03",
    "code": "300347"
  },
  {
    "title": "派格生物：泰格医药“突击”注资 两大核心药品均不具先发优势",
    "href": "http://stock.jrj.com.cn/ipo/2021/09/28083433527908.shtml",
    "datetime": "2021-09-28 08:34:00",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)获摩根大通增持27.53万股",
    "href": "http://stock.jrj.com.cn/2021/09/20072533464173.shtml",
    "datetime": "2021-09-20 07:25:42",
    "code": "300347"
  },
  {
    "title": "泰格医药副总经理高峻辞职 上半年公司净利12.55亿",
    "href": "http://stock.jrj.com.cn/2021/09/17215233453553.shtml",
    "datetime": "2021-09-17 21:52:14",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)：聘任曹晓春为公司财务负责人",
    "href": "http://stock.jrj.com.cn/2021/09/17174833452401.shtml",
    "datetime": "2021-09-17 17:48:41",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)：董事ZHUAN YIN减持期过半 未减持公司股份",
    "href": "http://stock.jrj.com.cn/2021/09/16182933446236.shtml",
    "datetime": "2021-09-16 18:29:33",
    "code": "300347"
  },
  {
    "title": "泰格医药(300347.SZ)：董事ZHUAN YIN减持期过半 未减持公司股份",
    "href": "http://stock.jrj.com.cn/2021/09/16174833445980.shtml",
    "datetime": "2021-09-16 17:48:38",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)9月16日耗资1319万元回购8.26万股A股",
    "href": "http://stock.jrj.com.cn/2021/09/16170833445702.shtml",
    "datetime": "2021-09-16 17:08:09",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)遭摩根大通减持13.47万股",
    "href": "http://stock.jrj.com.cn/2021/09/13081133426303.shtml",
    "datetime": "2021-09-13 08:11:31",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)：曹晓春质押220万股及解押250万股",
    "href": "http://stock.jrj.com.cn/2021/09/06170933392613.shtml",
    "datetime": "2021-09-06 17:09:07",
    "code": "300347"
  },
  {
    "title": "泰格医药(300347.SZ)：曹晓春质押220万股及解押250万股",
    "href": "http://stock.jrj.com.cn/2021/09/06164733392497.shtml",
    "datetime": "2021-09-06 16:47:17",
    "code": "300347"
  },
  {
    "title": "欧普康视、泰格医药涨超10%，科创创业50ETF(588390)大涨4%",
    "href": "http://stock.jrj.com.cn/2021/09/06143533391843.shtml",
    "datetime": "2021-09-06 14:35:38",
    "code": "300347"
  },
  {
    "title": "泰格医药高涨超6%，科创创业ETF(588360)盘中涨近3%",
    "href": "http://stock.jrj.com.cn/2021/09/06105933391206.shtml",
    "datetime": "2021-09-06 10:59:46",
    "code": "300347"
  },
  {
    "title": "派格生物无产品上市三年累亏4.3亿 第一大供应商泰格医药5000万突击入股",
    "href": "http://stock.jrj.com.cn/ipo/2021/09/06080033425007.shtml",
    "datetime": "2021-09-06 08:00:13",
    "code": "300347"
  },
  {
    "title": "派格生物无产品上市三年累亏4.3亿 第一大供应商泰格医药5000万突击入股",
    "href": "http://stock.jrj.com.cn/ipo/2021/09/06080033696532.shtml",
    "datetime": "2021-09-06 08:00:13",
    "code": "300347"
  },
  {
    "title": "泰格医药股价跌3.96% 上半年ROE毛利率均降",
    "href": "http://stock.jrj.com.cn/2021/09/02175633375133.shtml",
    "datetime": "2021-09-02 17:56:00",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)9月2日耗资3749.8万元回购28.41万股A股",
    "href": "http://stock.jrj.com.cn/2021/09/02165233374707.shtml",
    "datetime": "2021-09-02 16:52:07",
    "code": "300347"
  },
  {
    "title": "泰格医药(300347.SZ)：8月31日首次回购223.89万股A股",
    "href": "http://stock.jrj.com.cn/2021/09/01164433368088.shtml",
    "datetime": "2021-09-01 16:44:24",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)获NINETY ONE UK增持42.33万股",
    "href": "http://stock.jrj.com.cn/2021/08/31074033358379.shtml",
    "datetime": "2021-08-31 07:40:38",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)获BAILLIE GIFFORD & CO增持50.18万股",
    "href": "http://stock.jrj.com.cn/2021/08/31073833358376.shtml",
    "datetime": "2021-08-31 07:38:18",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)：防范不法分子假冒公司名义从事诈骗活动",
    "href": "http://stock.jrj.com.cn/2021/08/27202433335701.shtml",
    "datetime": "2021-08-27 20:24:34",
    "code": "300347"
  },
  {
    "title": "泰格医药股价再跌3.57% 上半年ROE毛利率均降",
    "href": "http://stock.jrj.com.cn/2021/08/27160733333650.shtml",
    "datetime": "2021-08-27 16:07:00",
    "code": "300347"
  },
  {
    "title": "泰格医药将花不超5亿元回购公司股份 用于股权激励",
    "href": "http://stock.jrj.com.cn/2021/08/26201433326530.shtml",
    "datetime": "2021-08-26 20:14:22",
    "code": "300347"
  },
  {
    "title": "泰格医药2021年半年度净利12.55亿元 同比净利增加25.65%",
    "href": "http://stock.jrj.com.cn/2021/08/25210033318892.shtml",
    "datetime": "2021-08-25 21:00:54",
    "code": "300347"
  },
  {
    "title": "泰格医药(300347.SZ)上半年净利升25.65%至12.55亿元",
    "href": "http://stock.jrj.com.cn/2021/08/25203833318690.shtml",
    "datetime": "2021-08-25 20:38:04",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)获花旗增持49.03万股",
    "href": "http://stock.jrj.com.cn/2021/08/19072833277859.shtml",
    "datetime": "2021-08-19 07:28:40",
    "code": "300347"
  },
  {
    "title": "泰格医药跌4% 西部证券上月喊买",
    "href": "http://stock.jrj.com.cn/2021/08/12163733243228.shtml",
    "datetime": "2021-08-12 16:37:00",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)遭贝莱德减持12.2万股",
    "href": "http://stock.jrj.com.cn/2021/08/11070333235454.shtml",
    "datetime": "2021-08-11 07:03:45",
    "code": "300347"
  },
  {
    "title": "泰格医药聘任吴灏为公司联席总裁 一季度公司净利4.55亿",
    "href": "http://stock.jrj.com.cn/2021/08/10203433233526.shtml",
    "datetime": "2021-08-10 20:34:43",
    "code": "300347"
  },
  {
    "title": "泰格医药(300347.SZ)：聘任吴灏为公司联席总裁",
    "href": "http://stock.jrj.com.cn/2021/08/10164233231948.shtml",
    "datetime": "2021-08-10 16:42:15",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)获Canada Pension Plan Investment Board增持13.18万股",
    "href": "http://stock.jrj.com.cn/2021/07/16065833104811.shtml",
    "datetime": "2021-07-16 06:58:08",
    "code": "300347"
  },
  {
    "title": "斥近百亿认购健康产业基金 泰格医药AH股齐涨",
    "href": "http://stock.jrj.com.cn/2021/07/13135633088710.shtml",
    "datetime": "2021-07-13 13:56:30",
    "code": "300347"
  },
  {
    "title": "国投招商、泰格医药联合领投，阿诺医药完成1亿美元D轮融资",
    "href": "http://stock.jrj.com.cn/2021/07/13112033088164.shtml",
    "datetime": "2021-07-13 11:20:08",
    "code": "300347"
  },
  {
    "title": "泰格医药(300347.SZ)：拟由政府收储杨家群地块以及子公司自用生产用地",
    "href": "http://stock.jrj.com.cn/2021/07/12205133084381.shtml",
    "datetime": "2021-07-12 20:51:11",
    "code": "300347"
  },
  {
    "title": "泰格医药跌近8%！医疗ETF（512170）半日吸金超6600万元",
    "href": "http://stock.jrj.com.cn/2021/07/08114833063391.shtml",
    "datetime": "2021-07-08 11:48:42",
    "code": "300347"
  },
  {
    "title": "CRO板块再度走弱 泰格医药跌超7%",
    "href": "http://stock.jrj.com.cn/2021/07/08100533062793.shtml",
    "datetime": "2021-07-08 10:05:58",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)近日签署《南京绿涌瑞华医健股权投资合伙企业(有限合伙)合伙协议》",
    "href": "http://stock.jrj.com.cn/2021/07/02173033034230.shtml",
    "datetime": "2021-07-02 17:30:24",
    "code": "300347"
  },
  {
    "title": "泰格医药控股股东曹晓春质押205万股 用于股权类投资",
    "href": "http://stock.jrj.com.cn/2021/06/28183433011193.shtml",
    "datetime": "2021-06-28 18:34:08",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)获贝莱德增持56.15万股",
    "href": "http://stock.jrj.com.cn/2021/06/24074932987126.shtml",
    "datetime": "2021-06-24 07:49:45",
    "code": "300347"
  },
  {
    "title": "A股异动 | 国际医学(000516.SZ)涨逾4% 携手泰格医药聚焦医药医疗产业平台深度融合",
    "href": "http://stock.jrj.com.cn/2021/06/17104732946228.shtml",
    "datetime": "2021-06-17 10:47:45",
    "code": "300347"
  },
  {
    "title": "国际医学(000516.SZ)：与泰格医药签订战略合作协议",
    "href": "http://stock.jrj.com.cn/2021/06/16160532940822.shtml",
    "datetime": "2021-06-16 16:05:34",
    "code": "300347"
  },
  {
    "title": "泰格医药(300347.SZ)：159.4517万股限制性股票将解除限售上市流通",
    "href": "http://stock.jrj.com.cn/2021/06/16152032940594.shtml",
    "datetime": "2021-06-16 15:20:19",
    "code": "300347"
  },
  {
    "title": "港股异动丨泰格医药AH齐跌 约159万股限售股6月21日解禁",
    "href": "http://stock.jrj.com.cn/2021/06/16104932939473.shtml",
    "datetime": "2021-06-16 10:49:31",
    "code": "300347"
  },
  {
    "title": "泰格医药：拟与其他投资方以投资生命健康产业为目的设预计总规模200亿元的合伙企业",
    "href": "http://stock.jrj.com.cn/2021/06/11193032912874.shtml",
    "datetime": "2021-06-11 19:30:11",
    "code": "300347"
  },
  {
    "title": "对标药明康德和泰格医药，第三方商业化平台百洋医药价值几何",
    "href": "http://stock.jrj.com.cn/2021/06/11131132910568.shtml",
    "datetime": "2021-06-11 13:11:57",
    "code": "300347"
  },
  {
    "title": "泰格医药(300347.SZ)：可解除限售的限制性股票共159.4519万股",
    "href": "http://stock.jrj.com.cn/2021/06/08180232894542.shtml",
    "datetime": "2021-06-08 18:02:30",
    "code": "300347"
  },
  {
    "title": "泰格医药控股股东曹晓春质押250万股 用于股权类投资",
    "href": "http://stock.jrj.com.cn/2021/06/07214432889069.shtml",
    "datetime": "2021-06-07 21:44:32",
    "code": "300347"
  },
  {
    "title": "泰格医药：部分限制性股票回购注销完成",
    "href": "http://stock.jrj.com.cn/2021/06/04180032875314.shtml",
    "datetime": "2021-06-04 18:00:55",
    "code": "300347"
  },
  {
    "title": "港股异动 | 泰格医药AH齐涨 与海南省人民医院达成战略合作",
    "href": "http://stock.jrj.com.cn/2021/06/04111132873202.shtml",
    "datetime": "2021-06-04 11:11:29",
    "code": "300347"
  },
  {
    "title": "泰格医药控股股东曹晓春质押250万股 用于股权类投资",
    "href": "http://stock.jrj.com.cn/2021/05/31200432852047.shtml",
    "datetime": "2021-05-31 20:04:41",
    "code": "300347"
  },
  {
    "title": "泰格医药(300347.SZ)：持股5%以上的曹晓春质押250万股",
    "href": "http://stock.jrj.com.cn/2021/05/31162132850204.shtml",
    "datetime": "2021-05-31 16:21:44",
    "code": "300347"
  },
  {
    "title": "泰格医药(300347.SZ)：2020年度权益分派10派3元 股权登记日5月31日",
    "href": "http://stock.jrj.com.cn/2021/05/25195932818174.shtml",
    "datetime": "2021-05-25 19:59:52",
    "code": "300347"
  },
  {
    "title": "泰格医药(300347.SZ)：董事及高管ZHUAN YIN拟减持不超257.4万股",
    "href": "http://stock.jrj.com.cn/2021/05/24215932812742.shtml",
    "datetime": "2021-05-24 21:59:09",
    "code": "300347"
  },
  {
    "title": "泰格医药(300347.SZ)：持股5%以上的曹晓春质押250万股",
    "href": "http://stock.jrj.com.cn/2021/05/24215732812736.shtml",
    "datetime": "2021-05-24 21:57:25",
    "code": "300347"
  },
  {
    "title": "泰格医药控股股东曹晓春质押250万股 用于股权类投资",
    "href": "http://stock.jrj.com.cn/2021/05/24200132812215.shtml",
    "datetime": "2021-05-24 20:01:52",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)：董事及高级管理人员ZHUAN YIN拟减持257.4万股",
    "href": "http://stock.jrj.com.cn/2021/05/24171532811171.shtml",
    "datetime": "2021-05-24 17:15:51",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)：持股5%以上股东质押250万股",
    "href": "http://stock.jrj.com.cn/2021/05/24171132811153.shtml",
    "datetime": "2021-05-24 17:11:45",
    "code": "300347"
  },
  {
    "title": "泰格医药：公司主营业务是临床I-IV期CRO研发服务",
    "href": "http://stock.jrj.com.cn/2021/04/30103232485347.shtml",
    "datetime": "2021-04-30 10:32:45",
    "code": "300347"
  },
  {
    "title": "泰格医药一季度营利双涨，净利润同比增长178.62%",
    "href": "http://stock.jrj.com.cn/2021/04/29102432478509.shtml",
    "datetime": "2021-04-29 10:24:59",
    "code": "300347"
  },
  {
    "title": "泰格医药(300347.SZ)一季度净利升78.65%至4.55亿元",
    "href": "http://stock.jrj.com.cn/2021/04/28200532473607.shtml",
    "datetime": "2021-04-28 20:05:29",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)获贝莱德增持11.91万股",
    "href": "http://stock.jrj.com.cn/2021/04/26075332451343.shtml",
    "datetime": "2021-04-26 07:53:55",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)遭FMR LLC减持15.59万股",
    "href": "http://stock.jrj.com.cn/2021/04/22080932420820.shtml",
    "datetime": "2021-04-22 08:09:19",
    "code": "300347"
  },
  {
    "title": "泰格医药：公司与睿智医药不属于同一细分行业",
    "href": "http://stock.jrj.com.cn/2021/04/20183932411270.shtml",
    "datetime": "2021-04-20 18:39:16",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)4月28日举行董事会会议审批一季度报告",
    "href": "http://stock.jrj.com.cn/2021/04/16164632387033.shtml",
    "datetime": "2021-04-16 16:46:59",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)获FIDELITY INVESTMENT TRUST增持12.51万股",
    "href": "http://stock.jrj.com.cn/2021/04/09075332338577.shtml",
    "datetime": "2021-04-09 07:53:18",
    "code": "300347"
  },
  {
    "title": "泰格医药“一口气”投资5家基金，出资达5.2亿元",
    "href": "http://stock.jrj.com.cn/2021/04/02102032269181.shtml",
    "datetime": "2021-04-02 10:20:09",
    "code": "300347"
  },
  {
    "title": "泰格医药2020年净利增长107.9% 董事长叶小平薪酬90.77万",
    "href": "http://stock.jrj.com.cn/2021/03/29221532243645.shtml",
    "datetime": "2021-03-29 22:15:48",
    "code": "300347"
  },
  {
    "title": "泰格医药(300347.SZ)2020年度扣非净利润升26.89%至7.08亿元 拟10派3元",
    "href": "http://stock.jrj.com.cn/2021/03/29182832242506.shtml",
    "datetime": "2021-03-29 18:28:54",
    "code": "300347"
  },
  {
    "title": "泰格医药年度报告：2020年度净利同比增长107.9% 拟10派3元",
    "href": "http://stock.jrj.com.cn/2021/03/29182632242493.shtml",
    "datetime": "2021-03-29 18:26:43",
    "code": "300347"
  },
  {
    "title": "泰格医药跌2.34% 高瓴资本安本标准等基金持股",
    "href": "http://stock.jrj.com.cn/2021/03/22165432194869.shtml",
    "datetime": "2021-03-22 16:54:00",
    "code": "300347"
  },
  {
    "title": "泰格医药跌8.5% 高瓴资本安本标准等基金持股",
    "href": "http://stock.jrj.com.cn/2021/03/15172332137486.shtml",
    "datetime": "2021-03-15 17:23:00",
    "code": "300347"
  },
  {
    "title": "泰格医药：加码股权激励 控股子公司DreamCIS拟推购股权计划",
    "href": "http://stock.jrj.com.cn/2021/03/09200932099425.shtml",
    "datetime": "2021-03-09 20:09:00",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)：韩国控股子公司DreamCIS计划采纳购股权计划",
    "href": "http://stock.jrj.com.cn/2021/03/09175632098644.shtml",
    "datetime": "2021-03-09 17:56:43",
    "code": "300347"
  },
  {
    "title": "泰格医药(300347.SZ)：子公司DreamCIS拟推出购股权计划",
    "href": "http://stock.jrj.com.cn/2021/03/09172732098421.shtml",
    "datetime": "2021-03-09 17:27:37",
    "code": "300347"
  },
  {
    "title": "泰格医药控股股东曹晓春质押75万股 用于股权类投资",
    "href": "http://stock.jrj.com.cn/2021/03/08200332092770.shtml",
    "datetime": "2021-03-08 20:03:03",
    "code": "300347"
  },
  {
    "title": "泰格医药跌11% 高瓴资本安本标准等基金持股",
    "href": "http://stock.jrj.com.cn/2021/03/08181832092257.shtml",
    "datetime": "2021-03-08 18:18:52",
    "code": "300347"
  },
  {
    "title": "泰格医药(300347.SZ)：持股5%以上股东曹晓春质押75万股",
    "href": "http://stock.jrj.com.cn/2021/03/08162832091454.shtml",
    "datetime": "2021-03-08 16:28:25",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)遭摩根大通减持29.84万股",
    "href": "http://stock.jrj.com.cn/2021/03/08072832088944.shtml",
    "datetime": "2021-03-08 07:28:21",
    "code": "300347"
  },
  {
    "title": "泰格医药跌6.19% 高瓴资本安本标准等基金持股",
    "href": "http://stock.jrj.com.cn/2021/03/04180632072030.shtml",
    "datetime": "2021-03-04 18:06:46",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)获贝莱德增持8.91万股",
    "href": "http://stock.jrj.com.cn/2021/03/04073532068481.shtml",
    "datetime": "2021-03-04 07:35:31",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)遭摩根士丹利减持17.97万股",
    "href": "http://stock.jrj.com.cn/2021/03/03082632061544.shtml",
    "datetime": "2021-03-03 08:26:25",
    "code": "300347"
  },
  {
    "title": "泰格医药跌5.85% 节后市值蒸发434亿元高瓴资本持股",
    "href": "http://stock.jrj.com.cn/2021/02/26175832034065.shtml",
    "datetime": "2021-02-26 17:58:00",
    "code": "300347"
  },
  {
    "title": "太刺激！欧普康视领跌11%，通策医疗、爱尔眼科、泰格医药等医药龙头再度暴跌！",
    "href": "http://stock.jrj.com.cn/2021/02/26113132031918.shtml",
    "datetime": "2021-02-26 11:31:38",
    "code": "300347"
  },
  {
    "title": "泰格医药跌9% 高瓴资本安本标准等基金持股",
    "href": "http://stock.jrj.com.cn/2021/02/22182032007202.shtml",
    "datetime": "2021-02-22 18:20:00",
    "code": "300347"
  },
  {
    "title": "广生堂(300436.SZ)：GST-HG141已完成Ia期临床试验暨确定泰格医药为Ib期临床试验CRO",
    "href": "http://stock.jrj.com.cn/2021/02/19191331993972.shtml",
    "datetime": "2021-02-19 19:13:03",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)获摩根士丹利增持29.7万股",
    "href": "http://stock.jrj.com.cn/2021/02/17070831967872.shtml",
    "datetime": "2021-02-17 07:08:31",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)遭FMR LLC减持22.91万股",
    "href": "http://stock.jrj.com.cn/2021/02/17070331967868.shtml",
    "datetime": "2021-02-17 07:03:15",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)遭NINETY ONE UK LIMITED减持28.46万股",
    "href": "http://stock.jrj.com.cn/2021/02/05072131852663.shtml",
    "datetime": "2021-02-05 07:21:22",
    "code": "300347"
  },
  {
    "title": "「2021新攻势」机构增持 国际投行上调目标价 泰格医药有哪些看点？",
    "href": "http://stock.jrj.com.cn/2021/02/03185431844441.shtml",
    "datetime": "2021-02-03 18:54:16",
    "code": "300347"
  },
  {
    "title": "泰格医药2020年预计净利16.83亿-18.1亿增长100%-115% 主营业务持续增长",
    "href": "http://stock.jrj.com.cn/2021/01/27213531793497.shtml",
    "datetime": "2021-01-27 21:35:51",
    "code": "300347"
  },
  {
    "title": "泰格医药业绩预告：2020年度净利润同比增长100%-115%",
    "href": "http://stock.jrj.com.cn/2021/01/27180831791587.shtml",
    "datetime": "2021-01-27 18:08:36",
    "code": "300347"
  },
  {
    "title": "CRO概念股集体走强 泰格医药、药明康德、康龙化成、药石科技均创历史新高",
    "href": "http://stock.jrj.com.cn/2021/01/22153331744884.shtml",
    "datetime": "2021-01-22 15:33:14",
    "code": "300347"
  },
  {
    "title": "康龙化成飙涨11%，泰格医药、药明康德涨超7%！CRO行业究竟发生了什么？",
    "href": "http://stock.jrj.com.cn/2021/01/20113631727647.shtml",
    "datetime": "2021-01-20 11:36:07",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)遭摩根大通减持91.63万股",
    "href": "http://stock.jrj.com.cn/2021/01/15080731696154.shtml",
    "datetime": "2021-01-15 08:07:14",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)获贝莱德增持8.62万股",
    "href": "http://stock.jrj.com.cn/2021/01/14090331688689.shtml",
    "datetime": "2021-01-14 09:03:57",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)遭摩根大通减持34.4万股",
    "href": "http://stock.jrj.com.cn/2020/12/29082531591296.shtml",
    "datetime": "2020-12-29 08:25:38",
    "code": "300347"
  },
  {
    "title": "泰格医药(3347.HK)一度涨近8%创上市新高",
    "href": "http://stock.jrj.com.cn/2020/12/28093531584527.shtml",
    "datetime": "2020-12-28 09:35:06",
    "code": "300347"
  },
  {
    "title": "泰格医药(300347.SZ)拉升涨超4% 续创历史新高",
    "href": "http://stock.jrj.com.cn/2020/12/25140131569649.shtml",
    "datetime": "2020-12-25 14:01:05",
    "code": "300347"
  },
  {
    "title": "泰格医药(300347.SZ)逼近160元再创历史新高 年内累涨超150% 市值逼近1400亿",
    "href": "http://stock.jrj.com.cn/2020/12/24152031561368.shtml",
    "datetime": "2020-12-24 15:20:54",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)购回及注销7.126万股A股股份",
    "href": "http://stock.jrj.com.cn/2020/12/23175731554797.shtml",
    "datetime": "2020-12-23 17:57:34",
    "code": "300347"
  },
  {
    "title": "港股异动 | 泰格医药(3347.HK)涨超4% 再创历史新高",
    "href": "http://stock.jrj.com.cn/2020/12/22102331542843.shtml",
    "datetime": "2020-12-22 10:23:06",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)获摩根大通增持14.67万股",
    "href": "http://stock.jrj.com.cn/2020/12/22081231541789.shtml",
    "datetime": "2020-12-22 08:12:07",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)遭摩根大通减持18.12万股",
    "href": "http://stock.jrj.com.cn/2020/12/21075631532499.shtml",
    "datetime": "2020-12-21 07:56:41",
    "code": "300347"
  },
  {
    "title": "富时罗素调整成分股，京东健康、泰格医药等获纳入",
    "href": "http://stock.jrj.com.cn/2020/12/18095531516546.shtml",
    "datetime": "2020-12-18 09:55:10",
    "code": "300347"
  },
  {
    "title": "沃森生物被指“贱卖”优质资产背后：泰格医药和北大系旧将浮出水面",
    "href": "http://stock.jrj.com.cn/2020/12/11071631462216.shtml",
    "datetime": "2020-12-11 07:16:36",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)获NINETY ONE UK LIMITED增持13.26万股",
    "href": "http://stock.jrj.com.cn/2020/12/09074231445680.shtml",
    "datetime": "2020-12-09 07:42:27",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)遭摩根大通减持139.85万股",
    "href": "http://stock.jrj.com.cn/2020/12/08085931436907.shtml",
    "datetime": "2020-12-08 08:59:34",
    "code": "300347"
  },
  {
    "title": "连涨7日 泰格医药(300347.SZ)再创历史新高",
    "href": "http://stock.jrj.com.cn/2020/12/07110831428275.shtml",
    "datetime": "2020-12-07 11:08:32",
    "code": "300347"
  },
  {
    "title": "泰格医药(300347.SZ)涨6% 连涨6日欲再创历史新高",
    "href": "http://stock.jrj.com.cn/2020/12/04141131407862.shtml",
    "datetime": "2020-12-04 14:11:00",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)遭NINETY ONE UK LIMITED减持11.19万股",
    "href": "http://stock.jrj.com.cn/2020/12/03071231396786.shtml",
    "datetime": "2020-12-03 07:12:59",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)获NINETY ONE UK LIMITED增持12.05万股",
    "href": "http://stock.jrj.com.cn/2020/11/05074231218431.shtml",
    "datetime": "2020-11-05 07:42:18",
    "code": "300347"
  },
  {
    "title": "泰格医药2020年前三季度净利13.18亿增长149.57% 其他收益增长",
    "href": "http://stock.jrj.com.cn/2020/11/01162331184085.shtml",
    "datetime": "2020-11-01 16:23:33",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)获摩根大通增持27.3万股",
    "href": "http://stock.jrj.com.cn/2020/10/16090831065580.shtml",
    "datetime": "2020-10-16 09:08:57",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)获NINETY ONE UK LIMITED增持20.69万股",
    "href": "http://stock.jrj.com.cn/2020/09/29080730857640.shtml",
    "datetime": "2020-09-29 08:07:25",
    "code": "300347"
  },
  {
    "title": "泰格医药：锚定临床CRO长远赛道 国际化发展加速 | 聚焦国内医药生物产业重要公司",
    "href": "http://stock.jrj.com.cn/2020/09/25144830835338.shtml",
    "datetime": "2020-09-25 14:48:06",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)获NINETY ONE UK LIMITED增持27.99万股",
    "href": "http://stock.jrj.com.cn/2020/09/25083830833327.shtml",
    "datetime": "2020-09-25 08:38:17",
    "code": "300347"
  },
  {
    "title": "CDE发布《药物临床试验数据监查委员会指导原则(试行)》 泰格医药拟2200万美元认购嘉和生物IPO股份|医资日报",
    "href": "http://stock.jrj.com.cn/2020/09/23180030818729.shtml",
    "datetime": "2020-09-23 18:00:05",
    "code": "300347"
  },
  {
    "title": "泰格医药(300347.SZ)：拟出资2.4亿元参投泰誉三期医疗器械基金",
    "href": "http://stock.jrj.com.cn/2020/09/23085030815029.shtml",
    "datetime": "2020-09-23 08:50:30",
    "code": "300347"
  },
  {
    "title": "泰格医药(300347.SZ)：子公司拟以基石投资者身份认购嘉和生物H股IPO股票",
    "href": "http://stock.jrj.com.cn/2020/09/23084630815030.shtml",
    "datetime": "2020-09-23 08:46:07",
    "code": "300347"
  },
  {
    "title": "泰格医药(03347.HK)获摩根士丹利增持20.06万股",
    "href": "http://stock.jrj.com.cn/2020/09/07091630690076.shtml",
    "datetime": "2020-09-07 09:16:00",
    "code": "300347"
  },
  {
    "title": "深交所：泰格医药调入港股通股票名单 今起生效",
    "href": "http://stock.jrj.com.cn/2020/08/31091030640946.shtml",
    "datetime": "2020-08-31 09:10:02",
    "code": "300347"
  },
  {
    "title": "泰格医药2020年上半年净利9.99亿增长184% 实验室服务产生收入增加",
    "href": "http://stock.jrj.com.cn/2020/08/30152030622605.shtml",
    "datetime": "2020-08-30 15:20:33",
    "code": "300347"
  },
  {
    "title": "泰格医药上半年净利润同比增长184%",
    "href": "http://stock.jrj.com.cn/2020/08/28222930617121.shtml",
    "datetime": "2020-08-28 22:29:34",
    "code": "300347"
  },
  {
    "title": "净利润激变有玄机 泰格医药晋身行业龙头路漫漫",
    "href": "http://stock.jrj.com.cn/2020/08/14070830496366.shtml",
    "datetime": "2020-08-14 07:08:26",
    "code": "300347"
  },
  {
    "title": "10省耗材带量采购价格信息公布 泰格医药港股上市募资金额达107亿港元 | 医资日报",
    "href": "http://stock.jrj.com.cn/2020/08/07184430451410.shtml",
    "datetime": "2020-08-07 18:44:56",
    "code": "300347"
  },
  {
    "title": "八类药品将退出医保药品目录 恒瑞医药上半年净利润超26亿元 | 医资日报",
    "href": "http://stock.jrj.com.cn/2020/08/03181030414446.shtml",
    "datetime": "2020-08-03 18:10:56",
    "code": "300347"
  },
  {
    "title": "泰格医药H股发行价确定为每股100港元 预计8月7日上市",
    "href": "http://stock.jrj.com.cn/2020/08/03122130412052.shtml",
    "datetime": "2020-08-03 12:21:47",
    "code": "300347"
  },
  {
    "title": "泰格医药通过港交所聆讯：募资最高15亿美元，即将启动招股",
    "href": "http://stock.jrj.com.cn/ipo/2020/07/20095230290622.shtml",
    "datetime": "2020-07-20 09:52:45",
    "code": "300347"
  },
  {
    "title": "泰格医药股东曹晓春减持200万股 套现约1.86亿元",
    "href": "http://stock.jrj.com.cn/2020/07/02182030124282.shtml",
    "datetime": "2020-07-02 18:20:35",
    "code": "300347"
  },
  {
    "title": "默沙东加入新冠疫苗研发赛道 泰格医药外资持股比例超预警线 | 医资日报",
    "href": "http://stock.jrj.com.cn/2020/05/28190629789447.shtml",
    "datetime": "2020-05-28 19:06:55",
    "code": "300347"
  },
  {
    "title": "泰格医药股东ZHUAN YIN拟减持股份 预计减持不超剔除回购专户股份后总股本0.31%",
    "href": "http://stock.jrj.com.cn/2020/05/14201629673659.shtml",
    "datetime": "2020-05-14 20:16:43",
    "code": "300347"
  },
  {
    "title": "泰格医药：持股1.37%董事及高级管理人员拟减持不超0.31%股份",
    "href": "http://stock.jrj.com.cn/2020/05/14175129672800.shtml",
    "datetime": "2020-05-14 17:51:43",
    "code": "300347"
  },
  {
    "title": "泰格医药股东曹晓春减持500万股 套现约3.71亿元",
    "href": "http://stock.jrj.com.cn/2020/05/09082529623903.shtml",
    "datetime": "2020-05-09 08:25:45",
    "code": "300347"
  },
  {
    "title": "泰格医药2020年第一季度净利2.55亿增长75.22% 出售非流动金融资产取得投资收益",
    "href": "http://stock.jrj.com.cn/2020/05/03162829500502.shtml",
    "datetime": "2020-05-03 16:28:52",
    "code": "300347"
  },
  {
    "title": "泰格医药向香港联交所递交境外上市外资股（H股）上市申请",
    "href": "http://stock.jrj.com.cn/2020/04/24082029364133.shtml",
    "datetime": "2020-04-24 08:20:54",
    "code": "300347"
  },
  {
    "title": "泰格医药发生大宗交易 成交溢价率5.96%",
    "href": "http://stock.jrj.com.cn/hotstock/2020/04/23205229360604.shtml",
    "datetime": "2020-04-23 20:52:00",
    "code": "300347"
  },
  {
    "title": "泰格医药与鸿运华宁生物医药签署《战略合作协议》",
    "href": "http://stock.jrj.com.cn/2020/04/22095729346113.shtml",
    "datetime": "2020-04-22 09:57:29",
    "code": "300347"
  },
  {
    "title": "泰格医药：与鸿运华宁生物医药战略合作",
    "href": "http://stock.jrj.com.cn/2020/04/21171629339439.shtml",
    "datetime": "2020-04-21 17:16:00",
    "code": "300347"
  },
  {
    "title": "泰格医药：发行H股申请材料获中国证监会受理",
    "href": "http://stock.jrj.com.cn/2020/04/19171629320721.shtml",
    "datetime": "2020-04-19 17:16:00",
    "code": "300347"
  },
  {
    "title": "泰格医药2019年度净利同比增78% 拟10派2.78元",
    "href": "http://stock.jrj.com.cn/2020/04/16214029307449.shtml",
    "datetime": "2020-04-16 21:40:16",
    "code": "300347"
  },
  {
    "title": "泰格医药：2019年净利润同比增长78% 拟10派2.78元",
    "href": "http://stock.jrj.com.cn/2020/04/16212929307417.shtml",
    "datetime": "2020-04-16 21:29:00",
    "code": "300347"
  },
  {
    "title": "泰格医药2020年一季度预计净利2.3亿元-2.74亿元 同比增长58%-88%",
    "href": "http://stock.jrj.com.cn/2020/04/07195929227742.shtml",
    "datetime": "2020-04-07 19:59:27",
    "code": "300347"
  },
  {
    "title": "泰格医药：2020年第一季度业绩报告预告",
    "href": "http://stock.jrj.com.cn/2020/04/07181029227177.shtml",
    "datetime": "2020-04-07 18:10:00",
    "code": "300347"
  },
  {
    "title": "泰格医药副总经理WEN CHEN辞职 2018年薪酬为112万元",
    "href": "http://stock.jrj.com.cn/2020/02/29155428919934.shtml",
    "datetime": "2020-02-29 15:54:54",
    "code": "300347"
  },
  {
    "title": "泰格医药2019年度盈利8.48亿增长80% 主营业务延续增长趋势",
    "href": "http://stock.jrj.com.cn/2020/02/28172328915579.shtml",
    "datetime": "2020-02-28 17:23:58",
    "code": "300347"
  },
  {
    "title": "泰格医药：拟1亿元投资富悦柏泽实业投资合伙企业 拓展公司投资渠道",
    "href": "http://stock.jrj.com.cn/2020/02/28154228914879.shtml",
    "datetime": "2020-02-28 15:42:08",
    "code": "300347"
  },
  {
    "title": "泰格医药：2019年初步净利润7.9亿元-9亿元 同比增长68%-91%",
    "href": "http://stock.jrj.com.cn/2020/01/10225728661241.shtml",
    "datetime": "2020-01-10 22:57:55",
    "code": "300347"
  },
  {
    "title": "泰格医药：2019年年度业绩报告预告",
    "href": "http://stock.jrj.com.cn/2020/01/10220028660340.shtml",
    "datetime": "2020-01-10 22:00:01",
    "code": "300347"
  },
  {
    "title": "泰格医药：2019年预盈7.95亿元-9亿元 同比增长68%-91%",
    "href": "http://stock.jrj.com.cn/2020/01/10212128660096.shtml",
    "datetime": "2020-01-10 21:21:52",
    "code": "300347"
  },
  {
    "title": "泰格医药：2019年度净利润预增68%至91%",
    "href": "http://stock.jrj.com.cn/2020/01/10211028660077.shtml",
    "datetime": "2020-01-10 21:10:00",
    "code": "300347"
  },
  {
    "title": "泰格医药：2019年度净利同比预增68%-91%",
    "href": "http://stock.jrj.com.cn/2020/01/10210628660028.shtml",
    "datetime": "2020-01-10 21:06:25",
    "code": "300347"
  },
  {
    "title": "泰格医药：预计2019年初利润7.9亿元-9亿元 同比增长68%-91%",
    "href": "http://stock.jrj.com.cn/2020/01/10204328659938.shtml",
    "datetime": "2020-01-10 20:43:01",
    "code": "300347"
  },
  {
    "title": "泰格医药实控人叶小平减持894.46万股 占公司总股本1.195%",
    "href": "http://stock.jrj.com.cn/2019/12/30213828605681.shtml",
    "datetime": "2019-12-30 21:38:27",
    "code": "300347"
  },
  {
    "title": "泰格医药：计划启动H股上市前期筹备工作",
    "href": "http://stock.jrj.com.cn/2019/12/13171428530577.shtml",
    "datetime": "2019-12-13 17:14:03",
    "code": "300347"
  },
  {
    "title": "泰格医药：计划启动H股上市的前期筹备工作",
    "href": "http://stock.jrj.com.cn/2019/12/13170328530553.shtml",
    "datetime": "2019-12-13 17:03:00",
    "code": "300347"
  },
  {
    "title": "泰格医药拟收购日本EPS部分股权 拓展亚太区业务",
    "href": "http://stock.jrj.com.cn/2019/10/29163428318566.shtml",
    "datetime": "2019-10-29 16:34:09",
    "code": "300347"
  },
  {
    "title": "泰格医药：拟收购日本EPS部分股权 拓展亚太区业务",
    "href": "http://stock.jrj.com.cn/2019/10/29163128318558.shtml",
    "datetime": "2019-10-29 16:31:00",
    "code": "300347"
  },
  {
    "title": "泰格医药：子公司拟1774万美元参股东京交易所上市药企EPS",
    "href": "http://stock.jrj.com.cn/2019/10/29161828318474.shtml",
    "datetime": "2019-10-29 16:18:47",
    "code": "300347"
  },
  {
    "title": "泰格医药第三季度盈利1.76亿 同比增长77.3%",
    "href": "http://stock.jrj.com.cn/2019/10/28085728308031.shtml",
    "datetime": "2019-10-28 08:57:19",
    "code": "300347"
  },
  {
    "title": "泰格医药：拟参与投资汇鼎医疗大健康基金",
    "href": "http://stock.jrj.com.cn/2019/10/16184728257478.shtml",
    "datetime": "2019-10-16 18:47:33",
    "code": "300347"
  },
  {
    "title": "泰格医药：拟参与投资博荃投资基金",
    "href": "http://stock.jrj.com.cn/2019/10/16184628257440.shtml",
    "datetime": "2019-10-16 18:46:18",
    "code": "300347"
  },
  {
    "title": "泰格医药：参与投资君联资本健康医疗人民币二期基金",
    "href": "http://stock.jrj.com.cn/2019/10/16184528257439.shtml",
    "datetime": "2019-10-16 18:45:16",
    "code": "300347"
  },
  {
    "title": "泰格医药拟与淡马锡旗下企业共同发起设立美元投资基金",
    "href": "http://stock.jrj.com.cn/2019/10/16184028257153.shtml",
    "datetime": "2019-10-16 18:40:08",
    "code": "300347"
  },
  {
    "title": "泰格医药：拟与淡马锡旗下企业共同发起设立美元投资基金",
    "href": "http://stock.jrj.com.cn/2019/10/16183628257111.shtml",
    "datetime": "2019-10-16 18:36:21",
    "code": "300347"
  },
  {
    "title": "泰格医药2019年前三季度净利5.21亿-5.41亿 主营业务保持良好发展趋势",
    "href": "http://stock.jrj.com.cn/2019/10/09210928223556.shtml",
    "datetime": "2019-10-09 21:09:23",
    "code": "300347"
  },
  {
    "title": "泰格医药：2019年前三季度业绩报告预告",
    "href": "http://stock.jrj.com.cn/2019/10/09193028223222.shtml",
    "datetime": "2019-10-09 19:30:00",
    "code": "300347"
  },
  {
    "title": "泰格医药：预计前三季度实现净利润5.2亿-5.4亿元",
    "href": "http://stock.jrj.com.cn/2019/10/09162428218474.shtml",
    "datetime": "2019-10-09 16:24:30",
    "code": "300347"
  },
  {
    "title": "泰格医药：前三季度净利预增64%-70%",
    "href": "http://stock.jrj.com.cn/2019/10/09161528218419.shtml",
    "datetime": "2019-10-09 16:15:11",
    "code": "300347"
  },
  {
    "title": "泰格医药董事及高级管理人员ZHUAN YIN拟减持股份 预计减持不超总股本0.11%",
    "href": "http://stock.jrj.com.cn/2019/09/04074728086022.shtml",
    "datetime": "2019-09-04 07:47:55",
    "code": "300347"
  },
  {
    "title": "泰格医药2019年上半年营收13.37亿 业务收入规模增长",
    "href": "http://stock.jrj.com.cn/2019/08/22202628018653.shtml",
    "datetime": "2019-08-22 20:26:35",
    "code": "300347"
  },
  {
    "title": "泰格医药上半年净利润同比增长61%",
    "href": "http://stock.jrj.com.cn/2019/08/22194428018468.shtml",
    "datetime": "2019-08-22 19:44:01",
    "code": "300347"
  },
  {
    "title": "泰格医药：拟8208万元收购北京雅信诚38%股权 整合临床翻译资源",
    "href": "http://stock.jrj.com.cn/2019/07/30184127904906.shtml",
    "datetime": "2019-07-30 18:41:19",
    "code": "300347"
  },
  {
    "title": "泰格医药监事施笑利合计减持188万股 套现约1.02亿元",
    "href": "http://stock.jrj.com.cn/2019/07/11072527824845.shtml",
    "datetime": "2019-07-11 07:25:47",
    "code": "300347"
  },
  {
    "title": "泰格医药：与阿斯利康战略合作",
    "href": "http://stock.jrj.com.cn/2019/07/05202927803250.shtml",
    "datetime": "2019-07-05 20:29:15",
    "code": "300347"
  },
  {
    "title": "泰格医药：与阿斯利康签订战略合作协议",
    "href": "http://stock.jrj.com.cn/2019/07/05200627803197.shtml",
    "datetime": "2019-07-05 20:06:59",
    "code": "300347"
  },
  {
    "title": "泰格医药与阿斯利康签订战略合作协议",
    "href": "http://stock.jrj.com.cn/2019/07/05200427803199.shtml",
    "datetime": "2019-07-05 20:04:06",
    "code": "300347"
  },
  {
    "title": "泰格医药香港子公司拟720万美元购买关联资产 溢价170%",
    "href": "http://stock.jrj.com.cn/2019/07/01163727778851.shtml",
    "datetime": "2019-07-01 16:37:01",
    "code": "300347"
  },
  {
    "title": "泰格医药2019年上半年净利3.72亿 较上年同期增长70%",
    "href": "http://stock.jrj.com.cn/2019/06/26072527756498.shtml",
    "datetime": "2019-06-26 07:25:43",
    "code": "300347"
  },
  {
    "title": "公告精选：泰格医药等业绩预增；科融环境拟将注册地搬迁至雄安新区",
    "href": "http://stock.jrj.com.cn/2019/06/25222427754934.shtml",
    "datetime": "2019-06-25 22:24:00",
    "code": "300347"
  },
  {
    "title": "泰格医药：2019年半年度业绩报告预告",
    "href": "http://stock.jrj.com.cn/2019/06/25201027754471.shtml",
    "datetime": "2019-06-25 20:10:08",
    "code": "300347"
  },
  {
    "title": "泰格医药：上半年净利预增50%至70%",
    "href": "http://stock.jrj.com.cn/2019/06/25183227754061.shtml",
    "datetime": "2019-06-25 18:32:03",
    "code": "300347"
  },
  {
    "title": "泰格医药：上半年净利预增50%-70%",
    "href": "http://stock.jrj.com.cn/2019/06/25175027753908.shtml",
    "datetime": "2019-06-25 17:50:00",
    "code": "300347"
  },
  {
    "title": "泰格医药股东曹晓春质押210万股 公司去年净利同比增长57%",
    "href": "http://stock.jrj.com.cn/2019/06/14073427702714.shtml",
    "datetime": "2019-06-14 07:34:17",
    "code": "300347"
  },
  {
    "title": "泰格医药：控股股东叶小平拟在6个月内减持不超1.52%",
    "href": "http://stock.jrj.com.cn/2019/06/05212127668897.shtml",
    "datetime": "2019-06-05 21:21:54",
    "code": "300347"
  },
  {
    "title": "泰格医药：控股股东拟减持公司不超1.52%股份",
    "href": "http://stock.jrj.com.cn/2019/06/05205527668815.shtml",
    "datetime": "2019-06-05 20:55:00",
    "code": "300347"
  },
  {
    "title": "泰格医药股东ZHUAN YIN减持175万股 套现约1.05亿元",
    "href": "http://stock.jrj.com.cn/2019/05/15081327573204.shtml",
    "datetime": "2019-05-15 08:13:41",
    "code": "300347"
  },
  {
    "title": "泰格医药去年净利4.72亿同比增长57% 董事长叶小平薪酬71万",
    "href": "http://stock.jrj.com.cn/2019/04/27102627495603.shtml",
    "datetime": "2019-04-27 10:26:17",
    "code": "300347"
  },
  {
    "title": "泰格医药股东曹晓春质押165万股 公司去年净利同比增长58%",
    "href": "http://stock.jrj.com.cn/2019/04/17073727413321.shtml",
    "datetime": "2019-04-17 07:37:57",
    "code": "300347"
  },
  {
    "title": "泰格医药：一季度净利预增40%～60%",
    "href": "http://stock.jrj.com.cn/2019/04/08200627347963.shtml",
    "datetime": "2019-04-08 20:06:00",
    "code": "300347"
  },
  {
    "title": "泰格医药：2019年第一季度业绩报告预告",
    "href": "http://stock.jrj.com.cn/2019/04/08195027347830.shtml",
    "datetime": "2019-04-08 19:50:00",
    "code": "300347"
  },
  {
    "title": "泰格医药：一季度净利预增40%-60%",
    "href": "http://stock.jrj.com.cn/2019/04/08174827347085.shtml",
    "datetime": "2019-04-08 17:48:20",
    "code": "300347"
  },
  {
    "title": "泰格医药股东曹晓春质押306万股 公司去年净利同比增长58%",
    "href": "http://stock.jrj.com.cn/2019/04/04074027318695.shtml",
    "datetime": "2019-04-04 07:40:14",
    "code": "300347"
  },
  {
    "title": "泰格医药：关于非公开发行股份解除限售的提示性公告",
    "href": "http://stock.jrj.com.cn/2019/01/29211026998472.shtml",
    "datetime": "2019-01-29 21:10:00",
    "code": "300347"
  },
  {
    "title": "泰格医药：18年净利预增49%-66% 商誉减值需留心",
    "href": "http://stock.jrj.com.cn/2019/01/08094026871571.shtml",
    "datetime": "2019-01-08 09:40:02",
    "code": "300347"
  },
  {
    "title": "泰格医药：2018年年度业绩报告预告",
    "href": "http://stock.jrj.com.cn/2019/01/03214026848907.shtml",
    "datetime": "2019-01-03 21:40:00",
    "code": "300347"
  },
  {
    "title": "2018年五大机构持仓透视 五大赚钱牛股浮出水面",
    "href": "http://stock.jrj.com.cn/2018/12/28012026815828.shtml",
    "datetime": "2018-12-28 01:20:42",
    "code": "300347"
  },
  {
    "title": "泰格医药：拟回购2.5亿-5亿元股份 价格不超过52元/股",
    "href": "http://stock.jrj.com.cn/2018/12/07175225472228.shtml",
    "datetime": "2018-12-07 17:52:05",
    "code": "300347"
  },
  {
    "title": "泰格医药：拟斥资2亿至5亿元回购股份",
    "href": "http://stock.jrj.com.cn/hotstock/2018/11/13080025337686.shtml",
    "datetime": "2018-11-13 08:00:01",
    "code": "300347"
  },
  {
    "title": "泰格医药：拟2亿至5亿元回购股份",
    "href": "http://stock.jrj.com.cn/2018/11/12201825334736.shtml",
    "datetime": "2018-11-12 20:18:00",
    "code": "300347"
  },
  {
    "title": "泰格医药：证监会对公司分拆方达医药境外上市事宜无异议",
    "href": "http://stock.jrj.com.cn/2018/11/09190025324519.shtml",
    "datetime": "2018-11-09 19:00:56",
    "code": "300347"
  },
  {
    "title": "泰格医药：证监会对公司分拆方达医药境外上市无异议",
    "href": "http://stock.jrj.com.cn/2018/11/09161825323710.shtml",
    "datetime": "2018-11-09 16:18:14",
    "code": "300347"
  },
  {
    "title": "泰格医药：证监会对公司分拆方达医药境外上市无异议",
    "href": "http://stock.jrj.com.cn/2018/11/09160625323684.shtml",
    "datetime": "2018-11-09 16:06:00",
    "code": "300347"
  }
]